📌 Why in News?
Syllabus: GS3/Science and Technology Synthetic DNA has become central to advances in health, food security, climate and biotechnology, but its growing accessibility has created significant dual-use and biosecurity risks. It is defined as artificially created genetic material that can be synthesized from digitized genome sequences and used to construct synthetic genomes.
Syllabus & Relevance
Prelims: Science & Technology — institutions, terminology and factual features connected with the development.
Mains: GS-3 — contemporary application of the relevant syllabus theme.
Current–static link: Revise the underlying institution, policy or concept together with this development.
Why it matters for India
**BioE3 Policy **Alignment: India’s BioE3 (Economy, Environment and Employment) Policy is a transition to a high-performing bio-economy driven by synthetic biology.
**BioE3 Policy **is helping to strengthen India’s position as a global powerhouse for biotechnology, supporting its rapidly growing bioeconomy.
India’s bioeconomy is estimated at US$ 165.7 billion in 2024, projected to touch US$ 300 billion by 2030.
Healthcare Self-Reliance: Enabling local creation of affordable medications, APIs and rapid diagnostics for the Indian population.
Static Foundation
It is defined as artificially created genetic material that can be synthesized from digitized genome sequences and used to construct synthetic genomes.
It expands the possibilities for the development of improved or entirely new biomolecular therapies, including enzymes, peptides, RNA catalysts, and DNA and RNA aptamers.
Medicine and Therapeutics: It promotes expeditious development of mRNA vaccines, tailored targeted gene treatments, **CRISPR-**based diagnostics, and synthetic monoclonal antibodies.
Agriculture & Food Systems: It engineers climate-resilient crops, nitrogen-fixing non-legume plants to reduce fertiliser consumption, and lab-grown alternative proteins.
Industrial Biotechnology: It aids in the bio-manufacturing of bioplastics, bio-fuels, specialised enzymes and high-value fine chemicals employing synthetic microbial factories.
Data Storage: It assists in using high-density DNA molecules as long-term, ultra-compact digital data storage media that can survive for millennia.
Global control of synthetic DNA has advanced from informal monitoring to more robust biosecurity mechanisms.
Data, Reports, Cases & Examples
Syllabus: GS3/Science and Technology
The 2010 guidance from the US Department of Health and Human Services (HHS) emphasised customer and sequence screening as important protections, which led to the establishment of the IGSC and its voluntary harmonised methodology.
IBBIS Common Mechanism (2024) will standardise worldwide screening and data sharing procedures, with support from programs at EBRC and RAND.
**BioE3 Policy **Alignment: India’s BioE3 (Economy, Environment and Employment) Policy is a transition to a high-performing bio-economy driven by synthetic biology.
**BioE3 Policy **is helping to strengthen India’s position as a global powerhouse for biotechnology, supporting its rapidly growing bioeconomy.
India’s bioeconomy is estimated at US$ 165.7 billion in 2024, projected to touch US$ 300 billion by 2030.
Prelims Quick Facts
Syllabus: GS3/Science and Technology
Synthetic DNA has become central to advances in health, food security, climate and biotechnology, but its growing accessibility has created significant dual-use and biosecurity risks.
It is defined as artificially created genetic material that can be synthesized from digitized genome sequences and used to construct synthetic genomes.
It expands the possibilities for the development of improved or entirely new biomolecular therapies, including enzymes, peptides, RNA catalysts, and DNA and RNA aptamers.
Medicine and Therapeutics: It promotes expeditious development of mRNA vaccines, tailored targeted gene treatments, **CRISPR-**based diagnostics, and synthetic monoclonal antibodies.
Agriculture & Food Systems: It engineers climate-resilient crops, nitrogen-fixing non-legume plants to reduce fertiliser consumption, and lab-grown alternative proteins.
Industrial Biotechnology: It aids in the bio-manufacturing of bioplastics, bio-fuels, specialised enzymes and high-value fine chemicals employing synthetic microbial factories.
Data Storage: It assists in using high-density DNA molecules as long-term, ultra-compact digital data storage media that can survive for millennia.
Mains-only layer✍️ Open Mains Perspective & Answer FrameworkClick to expand ↓
Mains Perspective
Background and key dimensions
- Medicine and Therapeutics: It promotes expeditious development of mRNA vaccines, tailored targeted gene treatments, **CRISPR-**based diagnostics, and synthetic monoclonal antibodies.
- Agriculture & Food Systems: It engineers climate-resilient crops, nitrogen-fixing non-legume plants to reduce fertiliser consumption, and lab-grown alternative proteins.
- Industrial Biotechnology: It aids in the bio-manufacturing of bioplastics, bio-fuels, specialised enzymes and high-value fine chemicals employing synthetic microbial factories.
- Data Storage: It assists in using high-density DNA molecules as long-term, ultra-compact digital data storage media that can survive for millennia.
- Global control of synthetic DNA has advanced from informal monitoring to more robust biosecurity mechanisms.
- The 2010 guidance from the US Department of Health and Human Services (HHS) emphasised customer and sequence screening as important protections, which led to the establishment of the IGSC and its voluntary harmonised methodology.
- European countries are slowly adding DNA screening to their national biosecurity programs and countries such as Nigeria, South Korea and China are also taking initiatives.
- IBBIS Common Mechanism (2024) will standardise worldwide screening and data sharing procedures, with support from programs at EBRC and RAND.
- Today governance is frequently three fold: mandatory screening at the provider level; self-regulation within the sector; and safeguards at the device level (e.g. user authentication, local sequence screening, recording and alarms).
- BioE3 Policy Alignment: India’s BioE3 (Economy, Environment and Employment) Policy is a transition to a high-performing bio-economy driven by synthetic biology.
- **BioE3 Policy **is helping to strengthen India’s position as a global powerhouse for biotechnology, supporting its rapidly growing bioeconomy.
- India’s bioeconomy is estimated at US$ 165.7 billion in 2024, projected to touch US$ 300 billion by 2030.
Analytical use
- Connect the development with its institutional, policy, economic, social, environmental or security implications only where supported above.
- In a Mains answer, separate the verified development from broader evaluation and use the named evidence precisely.
Way forward
- Base recommendations on the gaps and institutional responsibilities identified in the source-grounded points.
Answer Framework
Introduction
Begin with the immediate development and identify the central institution or policy issue.
Body
- Explain the relevant static concept.
- Present the principal source-backed facts.
- Analyse significance for India and the syllabus theme.
- Discuss supported challenges or implementation gaps.
- Use one named law, report, institution, date or example from the evidence box.
Conclusion
End with a balanced, institutionally feasible way forward without making claims beyond the available evidence.
Possible Mains Question
Examine the significance of “Securing Synthetic DNA in India”. Discuss its key implications and the way forward.